SAB Biotherapeutics, Inc. (SABS) is currently trading at $3.8 with a Wall Street consensus price target of $11.18, implying potential upside of 194.3% over the next 12 months. 11 analysts currently cover SABS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $6.0.
SABS operates in the Healthcare sector with a market capitalisation of $291M. The stock is up 0.8% year-to-date and is currently trading near the lower end of its 52-week range of $1.67 – $6.6.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for SABS, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →